HIV DNA vaccine (PENNVAX-G) - Inovio

Drug Profile

HIV DNA vaccine (PENNVAX-G) - Inovio

Alternative Names: HIV DNA vaccine against clades A, C and D - Inovio; PENNVAX G; PENNVAX-G DNA vaccine - Inovio/NIAID; PENNVAX-G-HIV-vaccine

Latest Information Update: 04 Jul 2017

Price : $50

At a glance

  • Originator University of Pennsylvania
  • Developer Inovio Pharmaceuticals
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 04 Jul 2017 Phase I development is ongoing in USA, Kenya, Uganda and Tanzania (Inovio Pharmaceuticals pipeline, July 2017)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections(Prevention, In volunteers) in Kenya (IM, Injection)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections(Prevention, In volunteers) in Tanzania (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top